http://localhost:8080/xmlui/handle/123456789/64 2026-01-20T23:35:59Z 2026-01-20T23:35:59Z REG NO: BT0122005 http://localhost:8080/xmlui/handle/123456789/2066 2026-01-13T10:22:28Z 2025-01-01T00:00:00Z

Title: An open label, non-randomized, interventional study to evaluate the efficacy and safety of microneedling combined with 5-fluorouracil 5% cream versus microneedling combined with tacrolimus 0.1% ointment versus microneedling alone in clinically stable vitiligo patients Authors: REG NO: BT0122005 Abstract: Background: Vitiligo is a chronic, acquired depigmentation disorder characterized by the selective destruction of melanocytes, leading to the appearance of white macules on the skin. It affects approximately 0.5% to 2% of the global population and has a profound psychosocial impact despite its non-life-threatening nature. Various treatment modalities exist, including topical immunosuppressants, phototherapy, and surgical interventions, but none guarantee universal efficacy. Microneedling has emerged as a promising approach to enhance repigmentation, particularly when combined with pharmacological agents such as 5-Fluorouracil (5-FU) and Tacrolimus. However, limited comparative studies exist evaluating the efficacy and safety of these combinations in stable vitiligo. Aim and Objective: The primary objective of this study is to compare the efficacy of microneedling alone versus microneedling combined with 5-FU 5% cream and microneedling combined with Tacrolimus 0.1% ointment in patients with stable vitiligo. The secondary objective is to assess the safety profile and patient satisfaction associated with these treatment modalities.

2025-01-01T00:00:00Z REG NO: BT0122004 http://localhost:8080/xmlui/handle/123456789/2065 2026-01-13T10:22:08Z 2025-01-01T00:00:00Z

Title: Comparison of efficacy of topical janus kinase inhibitor tofacitinib used alone versus used in combination with targeted narrow-band ultraviolet b (excimer) therapy Authors: REG NO: BT0122004 Abstract: ABSTRACT BACKGROUND A chronic skin disorder which occurs due to loss of melanocytes and manifests with patches of depigmentation is categorized as vitiligo. Despite various treatment modalities, including corticosteroids and phototherapy, no definitive cure exists. Recent advances highlight that Janus Kinase inhibitors such as Tofacitinib play a role in regulating the immune mechanism associated with the pathogenesis of vitiligo. Hence, this study was undertaken. to compare the effectiveness of topical Tofacitinib alone versus its combination with narrowband ultraviolet B (NBUVB) therapy. AIMS AND OBJECTIVES To compare the effectiveness of topical JAK inhibitor (Tofacitinib) alone versus used along with concomitant phototherapy on de-pigmented lesions of vitiligo and to determine the effect of topical JAK inhibitor (Tofacitinib) on pigmentation in vitiligo lesions.

2025-01-01T00:00:00Z REG NO: BT0122003 http://localhost:8080/xmlui/handle/123456789/2064 2026-01-13T10:21:48Z 2025-01-01T00:00:00Z

Title: An interventional study comparing Intralesional verapamil and Intralesional triamcinolone acetonide In the treatment of keloids in a Tertiary care hospital Authors: REG NO: BT0122003 Abstract: ABSTRACT · Background: Keloids is caused by abnormal hyperproliferation of dermal fibroblast, causing expansion beyond boundaries of insult. Intralesional (IL) triamcinolone acetonide (TAC) causes inhibition of fibroblast. Intralesional verapamil, a calcium channel blocker activates procollagenase causing depolymerization of actin, inhibiting incorporation of proline and slowing action potential by which it reduces pain and pruritis associated with keloids. This study compares both the modalities for treatment of keloids. · Aims and Objectives: To assess and compare the efficacy, safety, reduction in pain and pruritis and side effects between intralesional verapamil hydrochloride and triamcinolone acetonide in treatment of keloid in patient aged 18 to 70 years.

2025-01-01T00:00:00Z REG N0: BT0122002 http://localhost:8080/xmlui/handle/123456789/2063 2026-01-13T10:21:24Z 2025-01-01T00:00:00Z

Title: An open label non-randomized split face interventional study to compare the efficacy and safety of microneedling with azelaic acid 10% gel versus microneedling with tranexamic acid 5% gel in the treatment of melasma. Authors: REG N0: BT0122002 Abstract: PRIMARY OBJECTIVE: To compare the efficacy of microneedling with azelaic acid 10 % gel versus microneedling with tranexamic acid 5% gel in the treatment of melasma. SECONDARY OBJECTIVE: 1. To compare the safety of microneedling with azelaic acid 10 % gel versus microneedling with tranexamic acid 5% gel in the treatment of melasma. 2. To assess and compare Melasma Quality of Life (MelasQoL) score at the beginning and at end of the study.

2025-01-01T00:00:00Z